PT  - JOURNAL ARTICLE
AU  - BASU, SANDIP
AU  - Fargose, Preeti
TI  - <sup>177</sup>Lu-DOTATATE  PRRT as promising new treatment approach in Recurrent Skull Base Phosphaturic Mesenchymal Tumor causing paraneoplastic oncogenic osteomalacia: a potential therapeutic application of PRRT beyond NET
AID  - 10.2967/jnmt.116.177873
DP  - 2016 Sep 01
TA  - Journal of Nuclear Medicine Technology
PG  - jnmt.116.177873
4099  - http://tech.snmjournals.org/content/early/2016/09/14/jnmt.116.177873.short
4100  - http://tech.snmjournals.org/content/early/2016/09/14/jnmt.116.177873.full
AB  - The potential of peptide receptor radionuclide therapy (PRRT) is described in recurrent inoperable phosphaturic mesenchymal tumor involving left basi-occiput causing tumor-induced osteomalacia (TIO), for which the patient had undergone two times surgery previously. Following one cycle of PRRT, there was good symptomatic improvement, modest reduction of uptake on both 68Ga-DOTATATE PET/CT and FDG-PET/CT suggesting favourable response and hence was considered for second cycle. Being somatostatin receptor avid, this rare group of tumors when inoperable or recurrent may be potentially targeted with PRRT. Well-tolerated and non-invasive, PRRT could evolve as a promising targeted treatment approach in this clinical setting. In summary, TIO with 68Ga-DOTATATE avid inoperable/recurrent tumor can be considered as a potential and novel clinical treatment application of PRRT beyond neuroendocrine tumors.